Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

trial failure

This page shows the latest trial failure news and features for those working in and with pharma, biotech and healthcare.

Blow for Entresto in latest heart failure trial

Blow for Entresto in latest heart failure trial

Aim of being first in HFpEF in serious doubt. Novartis’ heart failure drug Entrestro (Sacubitril/valsartan) has narrowly missed its primary endpoint in a trial of patients with preserved ejection fraction ... HFpEF). The results came from the

Latest news

  • Keytruda scores in neoadjuvant triple negative breast cancer combo Keytruda scores in neoadjuvant triple negative breast cancer combo

    In this trial, Keytruda showed improvement regardless of PD-1 status of patients. ... The results are a big boost after the failure of its second line treatment trial, but analysts say that neoadjuvant is currently a small opportunity in triple negative

  • FDA fast-tracks Jardiance for heart failure review FDA fast-tracks Jardiance for heart failure review

    Lilly and Boehringer are pursuing the drug’s use in heart failure patients in their EMPEROR trial programme. ... A product which has opened up the heart failure market in recent years is Novartis’ Entresto.

  • Roche to present new data on Spinraza rival Roche to present new data on Spinraza rival

    One patient died from respiratory failure in a separate European trial of Zolgensma, but the incident was found to be unrelated to the gene therapy following an investigation. ... Last month, another patient death occurred during the phase 3 STR1VE trial,

  • J&J’s Invokana first SGLT2 to show kidney disease benefits J&J’s Invokana first SGLT2 to show kidney disease benefits

    Results from the CREDENCE study, which evaluated type 2 diabetes patients with chronic kidney disease, showed that those taking the once-daily pill had a 30% lower risk of kidney failure, ... The trial puts Invokana one step ahead of rivals, such as

  • Undeterred by aducanumab failure, Eisai and Biogen plough on Undeterred by aducanumab failure, Eisai and Biogen plough on

    Investors sceptical, though mechanism different. Mere hours after reporting the failure of aducanumab in Alzheimer’s disease, Eisai has cued up a phase 3 trial of BAN2401, another amyloid-targeted drug. ... BAN2401 has been seen as something of an

More from news
Approximately 26 fully matching, plus 64 partially matching documents found.

Latest Intelligence

  • For trials without tribulations, we must improve patient experience For trials without tribulations, we must improve patient experience

    The result of this consultation is Havas Lynx Group’s latest white paper‘Patient Centricity on Trial’. ... This kind of simple, practical question can be the difference between success and failure of a clinical trial, and is usually only raised by

  • VIDEO interview: Neil Weir, UCB VIDEO interview: Neil Weir, UCB

    Avoiding failure. By taking this approach to research, it's possible to avoid one of the major pitfalls facing pharma today – the high cost of late-stage trial failure. ... Particularly when we have high failure rates in late stages in clinical studies,

  • Customer valuation in pharma Customer valuation in pharma

    Multiple studies have pegged the probability of clinical trial success at between 13-20 per cent. ... This estimate has remained constant over decades. Among the major reasons for clinical trial failure are problems that rest squarely in the domain of

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Alzheimer's: the numbers we cannot forget

    This is one of the highest clinical trial failure rates in healthcare. ... Failures in these trials have been associated with lack of efficacy, excessive side effects, or challenges in trial execution; leaving patients and HCPs with 5 therapies to choose

  • A forward march for adaptive designs

    For example, poor dose selection in phase II is frequently cited as one of the top causes of late-stage clinical trial failure. ... As such, it has prioritised phase II/III adaptive trial designs as well as other types of study.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Quick links

Infographics

Multimedia